Cited 0 times in Scipus Cited Count

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

DC Field Value Language
dc.contributor.authorPark, KH-
dc.contributor.authorLee, S-
dc.contributor.authorPark, JH-
dc.contributor.authorKang, SY-
dc.contributor.authorKim, HY-
dc.contributor.authorPark, IH-
dc.contributor.authorPark, YH-
dc.contributor.authorIm, YH-
dc.contributor.authorLee, HJ-
dc.contributor.authorPark, S-
dc.contributor.authorLee, SI-
dc.contributor.authorJung, KH-
dc.contributor.authorKim, YS-
dc.contributor.authorSeo, JH-
dc.date.accessioned2018-07-27T00:51:43Z-
dc.date.available2018-07-27T00:51:43Z-
dc.date.issued2017-
dc.identifier.issn0941-4355-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15523-
dc.description.abstractPURPOSE: This multi-center, randomized, phase III study was conducted to demonstrate the non-inferiority of DA-3031 compared with daily filgrastim in patients during the first cycle of chemotherapy for breast cancer in terms of the duration of severe neutropenia (DSN).
METHODS: Seventy-four patients with breast cancer who were receiving combination chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) were enrolled. All participants were randomized to receive either daily subcutaneous injections of filgrastim 100 mug/m(2)/day for up to 10 days or a single subcutaneous injection of DA-3031 at fixed doses of 6 mg on day 2 of each chemotherapy cycle.
RESULTS: The mean duration of grade 4 (G4) neutropenia in cycle 1 was 2.08 +/- 0.85 days for the filgrastim group and 2.28 +/- 1.14 days for the DA-3031 group. The difference between groups was 0.2 +/- 1.10 days (95 % confidence interval (CI) = -0.26, 0.66), which supported non-inferiority. No statistically significant differences were observed in nadir absolute neutrophil count (ANC) (154.34/mm(3) and 161.75/mm(3) for the filgrastim and DA-3031 groups, respectively: P = 0.8414) or in time to ANC recovery (10.03 +/- 0.75 and 9.83 +/- 1.56 days in the filgrastim and DA-3031 groups, respectively: P = 0.0611) during cycle 1. Serious AEs occurred in six (15.8 %) patients receiving filgrastim and in ten (27.8 %) patients receiving DA-3031: however, none was determined to be related to the study drug.
CONCLUSIONS: DA-3031 and daily filgrastim are similar in regard to DSN and safety in breast cancer patients receiving TAC chemotherapy.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBreast Neoplasms-
dc.subject.MESHChemotherapy-Induced Febrile Neutropenia-
dc.subject.MESHCyclophosphamide-
dc.subject.MESHDoxorubicin-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHFilgrastim-
dc.subject.MESHGranulocyte Colony-Stimulating Factor-
dc.subject.MESHHumans-
dc.subject.MESHInjections, Subcutaneous-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPolyethylene Glycols-
dc.subject.MESHTaxoids-
dc.titleA randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer-
dc.typeArticle-
dc.identifier.pmid27709313-
dc.contributor.affiliatedAuthor강, 석윤-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s00520-016-3429-2-
dc.citation.titleSupportive care in cancer-
dc.citation.volume25-
dc.citation.number2-
dc.citation.date2017-
dc.citation.startPage505-
dc.citation.endPage511-
dc.identifier.bibliographicCitationSupportive care in cancer, 25(2). : 505-511, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1433-7339-
dc.relation.journalidJ009414355-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse